Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoradiation with 5-FU/Cisplatin vs Gemcitabine for Bladder Preservation
NCT00777491Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Dec 2008
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of gemcitabine in bladder cancer (2 arms), sponsored by NRG Oncology. Primary endpoint: Percentage of Patients Without Distant Metastases by Three Years at 3 years. Started Dec 2008; status: completed.
02
Drugs
gemcitabine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00777491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00777491.